Cargando…

Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis

BACKGROUND: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which primarily affects the axial skeleton resulting in chronic back pain and stiffness. According to the guideline, the first-line treatment includes non-steroidal anti-inflammatory drugs (NSAIDs), conventional synthetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kahn, Maria, Papukchieva, Steffeni, Fehr, Axel, Eberl, Markus, Rösler, Berenice, Veit, Justyna, Friedrich, Benjamin, Poddubnyy, Denis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411271/
https://www.ncbi.nlm.nih.gov/pubmed/37565049
http://dx.doi.org/10.1177/1759720X231187189
_version_ 1785086628640849920
author Kahn, Maria
Papukchieva, Steffeni
Fehr, Axel
Eberl, Markus
Rösler, Berenice
Veit, Justyna
Friedrich, Benjamin
Poddubnyy, Denis
author_facet Kahn, Maria
Papukchieva, Steffeni
Fehr, Axel
Eberl, Markus
Rösler, Berenice
Veit, Justyna
Friedrich, Benjamin
Poddubnyy, Denis
author_sort Kahn, Maria
collection PubMed
description BACKGROUND: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which primarily affects the axial skeleton resulting in chronic back pain and stiffness. According to the guideline, the first-line treatment includes non-steroidal anti-inflammatory drugs (NSAIDs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and non-pharmacological treatment. Second line treatment involves biological disease-modifying antirheumatic drugs (bDMARDs) such as tumour necrosis factor and interleukin-17 inhibitors. OBJECTIVES: The aim of this social media listening research project was to analyse switches of medication and the reasons thereof to gain valuable insights into real-life journeys of patients suffering from axSpA. METHODS: Publicly available posts in German-speaking disease-specific forums were scanned for disease-specific keywords and commonly used drugs by axSpA patients on the Permea platform. Posts containing at least two key words were selected and switches between medications were manually labelled. A total of 287 scraped posts between 01 July 2010 and 04 Feb 2022 were analysed. RESULTS: The largest group of described medication switches was initially using bDMARDs. Switches to a different bDMARD, termination of medication and switches to glucocorticoids were most frequently named. Patients on NSAIDs switched to glucocorticoids, a different NSAID or bDMARD, whereas patients on csDMARDs most frequently changed to bDMARDs. In all medication groups the main reason for switching was insufficient efficacy and side effects. Additionally, for the medication groups bDMARDs, csDMARDs and corticosteroids, pregnancy and lactation were given as a reason for switching, whereas patients in the NSAID group never mentioned pregnancy and breastfeeding as a reason for switching treatment. CONCLUSION: Our analysis shows medication switches based on real-life patient experiences shared with peers in a social listening setting. We also show medication switches differing from advised guidelines. Gathering real-life insights into patients’ journey dealing with chronic diseases allows us to understand, and thereby improve patient care and treatment.
format Online
Article
Text
id pubmed-10411271
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-104112712023-08-10 Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis Kahn, Maria Papukchieva, Steffeni Fehr, Axel Eberl, Markus Rösler, Berenice Veit, Justyna Friedrich, Benjamin Poddubnyy, Denis Ther Adv Musculoskelet Dis Original Research BACKGROUND: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which primarily affects the axial skeleton resulting in chronic back pain and stiffness. According to the guideline, the first-line treatment includes non-steroidal anti-inflammatory drugs (NSAIDs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and non-pharmacological treatment. Second line treatment involves biological disease-modifying antirheumatic drugs (bDMARDs) such as tumour necrosis factor and interleukin-17 inhibitors. OBJECTIVES: The aim of this social media listening research project was to analyse switches of medication and the reasons thereof to gain valuable insights into real-life journeys of patients suffering from axSpA. METHODS: Publicly available posts in German-speaking disease-specific forums were scanned for disease-specific keywords and commonly used drugs by axSpA patients on the Permea platform. Posts containing at least two key words were selected and switches between medications were manually labelled. A total of 287 scraped posts between 01 July 2010 and 04 Feb 2022 were analysed. RESULTS: The largest group of described medication switches was initially using bDMARDs. Switches to a different bDMARD, termination of medication and switches to glucocorticoids were most frequently named. Patients on NSAIDs switched to glucocorticoids, a different NSAID or bDMARD, whereas patients on csDMARDs most frequently changed to bDMARDs. In all medication groups the main reason for switching was insufficient efficacy and side effects. Additionally, for the medication groups bDMARDs, csDMARDs and corticosteroids, pregnancy and lactation were given as a reason for switching, whereas patients in the NSAID group never mentioned pregnancy and breastfeeding as a reason for switching treatment. CONCLUSION: Our analysis shows medication switches based on real-life patient experiences shared with peers in a social listening setting. We also show medication switches differing from advised guidelines. Gathering real-life insights into patients’ journey dealing with chronic diseases allows us to understand, and thereby improve patient care and treatment. SAGE Publications 2023-08-08 /pmc/articles/PMC10411271/ /pubmed/37565049 http://dx.doi.org/10.1177/1759720X231187189 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Kahn, Maria
Papukchieva, Steffeni
Fehr, Axel
Eberl, Markus
Rösler, Berenice
Veit, Justyna
Friedrich, Benjamin
Poddubnyy, Denis
Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis
title Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis
title_full Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis
title_fullStr Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis
title_full_unstemmed Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis
title_short Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis
title_sort drug switching in axial spondyloarthritis patients in germany – a social listening analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411271/
https://www.ncbi.nlm.nih.gov/pubmed/37565049
http://dx.doi.org/10.1177/1759720X231187189
work_keys_str_mv AT kahnmaria drugswitchinginaxialspondyloarthritispatientsingermanyasociallisteninganalysis
AT papukchievasteffeni drugswitchinginaxialspondyloarthritispatientsingermanyasociallisteninganalysis
AT fehraxel drugswitchinginaxialspondyloarthritispatientsingermanyasociallisteninganalysis
AT eberlmarkus drugswitchinginaxialspondyloarthritispatientsingermanyasociallisteninganalysis
AT roslerberenice drugswitchinginaxialspondyloarthritispatientsingermanyasociallisteninganalysis
AT veitjustyna drugswitchinginaxialspondyloarthritispatientsingermanyasociallisteninganalysis
AT friedrichbenjamin drugswitchinginaxialspondyloarthritispatientsingermanyasociallisteninganalysis
AT poddubnyydenis drugswitchinginaxialspondyloarthritispatientsingermanyasociallisteninganalysis